Ucyclyd Buphenyl reimbursement to be managed by Corning HTA; orphan drug approved April 30.
UCYCLYD BUPHENYL REIMBURSEMENT NEGOTIATION TO BE HANDLED BY CORNING HTA following FDA approval of the powder version of the orphan drug for urea cycle disorders April 30. Ucyclyd has contracted with Washington, D.C.-based Corning HTA to conduct a provider-insurance program to assist in transitioning urea cycle patients on Buphenyl (sodium phenylbutyrate) from the clinical trials in which they are currently receiving the drug free of charge to a reimbursement setting with insurance companies, Corning HTA said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth